Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations. (3rd April 2022)

• Record Type: Journal Article
• Authors: Power, John R.; Keyt, Lucas K.; Adler, Eric D.
• Is Part Of: Expert review of cardiovascular therapy. Volume 20:Number 4(2022)
• Page Start: 241
• Page End: 251
• Publication Date: 2022-04-03
• Subjects: Myocarditis -- COVID-19 -- vaccine -- incidence -- molecular mimicry -- innate immune system -- in vitro transcribed mRNA -- clinical; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2022.2066522
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Introduction: Vaccines have demonstrated protection against the morbidity and mortality of COVID-19, but concerns regarding the rare side effect of acute myocarditis have stymied immunization efforts. This review aims to describe the incidence and theorized mechanisms of COVID vaccine-associated myocarditis and review relevant principles for management of vaccine-associated myocarditis Areas covered: Epidemiologic studies of myocarditis after COVID vaccination are reviewed, which show an incidence of approximately 20–30 per million patients. The vast majority of these cases are seen with mRNA vaccines especially in male patients under 30 years of age. Mechanisms are largely theoretical, but molecular mimicry and dysregulated innate immune reactions have been proposed. While studies suggest that this subtype of myocarditis is mild and self-limited, long-term evidence is lacking. Principles of myocarditis treatment and surveillance are outlined as they apply to COVID vaccine-associated myocarditis. Expert Opinion: COVID vaccine-associated myocarditis is rare but well described in certain at-risk groups. Better understanding of its pathogenesis is key to mitigating this complication and advancing vaccination efforts. Risk-benefit analyses demonstrate that individual- and population-level benefits of vaccination exceed the risks of this rare and mild form of myocarditis.